Clinical development of CTX-177 under a license agreement with Ono Pharmaceutical Co., Ltd.
First written in FY2024-Q3. 3 of 7 entries say "Advanced", first in FY2024. Latest entry: 2026-10-15.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「In February 2026, we entered into a termination agreement setting out specific procedures and detailed terms for the transfer of data. As a result, the relevant data and other materials were transferred to us free of charge, and upon termination of the license agreement, we reacquired all worldwide rights to CTX-177. At present, we are actively seeking a new partner, considering execution of a license agreement with a new partner as one option.」
For CTX-177, a termination agreement was signed in February 2026, formalizing the transfer of related data and reacquisition of worldwide rights. The search for a new licensee continues. - FY2025ReframedAnnual report
「However, on 28 April 2025, we received notice from 小野薬品工業 that it would discontinue the clinical trials based on a strategic decision, and accordingly we recovered the relevant rights. As of the end of the fiscal year, we hold the exclusive worldwide rights to research, develop, manufacture and commercialize the compound. We are currently considering the selection of a new licensee.」
Following 小野薬品工業’s discontinuation of the clinical trials and termination of the license agreement, worldwide rights to CTX-177 returned to the company, and the plan shifted to selecting a new licensee. - FY2025-H1RestatedAnnual report
「For the MALT1 inhibitor CTX-177, under the license agreement signed with 小野薬品工業株式会社 in December 2020, 小野薬品工業株式会社 has been steadily advancing clinical trials and is currently conducting Phase 1 clinical trials in the United States and Japan in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.」
The Phase 1 trials under the license agreement with 小野薬品工業 continue in the United States and Japan. - FY2024AdvancedAnnual report
「In February 2023, we received a development milestone payment of ¥2.5 billion. We are also entitled to receive up to ¥49.6 billion in future milestone payments based on development progress and sales, as well as royalties based on worldwide sales.」
For CTX-177, receipt of the initial ¥2.5 billion development milestone payment in connection with progress in the U.S. Phase 1 trial was disclosed, along with the maximum amount of future milestone payments. - FY2024-Q3First statedAnnual report
「For the MALT1 inhibitor CTX-177, under the license agreement signed with 小野薬品工業株式会社 in December 2020, 小野薬品工業株式会社 is conducting a Phase 1 clinical trial in the United States in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.」
Under the license agreement signed in December 2020, the partner is conducting a Phase 1 trial in the United States.